SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of August 2025
Commission File Number 000-38512
Oncolytics Biotech Inc.
(Translation of registrant’s name into
English)
Suite 804, 322 11th Avenue SW
Calgary, Alberta, Canada T2R 0C5
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
INCORPORATION BY REFERENCE
Exhibit 99.1 set forth below on this Form 6-K
is hereby incorporated by reference as an exhibit to the Registration Statement on Form F-10 of Oncolytics Biotech Inc. (File No. 333-281009),
as amended or supplemented.
DOCUMENTS FILED
EXHIBIT
NUMBER |
|
DESCRIPTION |
| |
|
|
| 99.1 |
|
Information Circular, incorporated by reference to Exhibit 99.1 to the registrant’s Foreign Issuer Report on Form 6-K as filed with the Commission on July 8, 2025. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
Oncolytics Biotech Inc.
(Registrant) |
| |
|
|
| |
|
|
| Date: August 8, 2025 |
By: |
/s/ Kirk Look |
| |
|
Kirk Look |
| |
|
Chief Financial Officer |
